All articles tagged with #macular edema
Ollin Biosciences raised $330 million in a Series B to push its eye-disease therapy into Phase 3 trials for diabetic macular edema and wet age-related macular degeneration, with lead investors including TCGX and ARCH Venture Partners and participation from a pension fund and crossover investors, in one of biotech’s largest Series B rounds in years.
A medical board examined Imran Khan in Adiala jail, reporting right-eye vision of 6/36 unaided improving to 6/9 with glasses, and left-eye vision 6/6; slit-lamp results showed clear corneas with notable retinal changes in the right eye, including mild intravitreal hemorrhage, disc hyperemia, and moderately dense retinal hemorrhages with cotton-wool spots, while the left eye was normal. Optical coherence tomography confirmed resolving macular edema with central macular thickness dropping from 550 to 350. The panel recommended Nevanac, Co-Sopt, and Systane eye drops and noted a possible second anti-VEGF dose. Officials said the update satisfied Khan’s personal physicians and political leaders amid previous concerns over the inspection’s timing and transparency.
A clinical trial funded by the National Eye Institute (NEI) has found that repeat treatment with corticosteroid injections is the most effective therapy for persistent or recurrent uveitis-related macular edema, a major cause of vision loss in people with uveitis. The corticosteroid treatment achieved greater reductions in retinal swelling and was the only therapy in the study that improved vision. The study compared three treatments for uveitis-related macular edema: an additional intraocular corticosteroid injection, an injection of the anti-vascular endothelial growth factor (anti-VEGF) drug ranibizumab, or an injection of the anti-inflammatory drug methotrexate.